Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages

Michael S. Lee, E. Claire Dees, Andrew Z. Wang

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations

Abstract

Cytotoxic chemotherapies have a narrow therapeutic window, with high peaks and troughs of plasma concentration. Novel nanoparticle formulations of cytotoxic chemotherapy drugs can enhance pharmacokinetic characteristics and facilitate passive targeting of drugs to tumors via the enhanced permeability and retention effect, thus mitigating toxicity. Nanoparticle vehicles currently in clinical use or undergoing clinical investigation for anticancer therapies include liposomes, polymeric micelles, protein-drug nanoparticles, and dendrimers. Multiple nanoparticle formulations of existing cytotoxic chemotherapies are approved for use in several indications, with clinical data indeed showing optimization of pharmacokinetics and different toxicity profiles compared with their parent drugs. There are also many new nanoparticle drug formulations in development and undergoing early- and late-phase clinical trials, including several that utilize active targeting or triggered release based on environmental stimuli. Here, we review the rationale for nanoparticle formulations of existing or previously investigated cytotoxic drugs, describe currently approved nanoparticle formulations of drugs, and discuss some of the most promising clinical trials currently underway.

Original languageEnglish (US)
Pages (from-to)198-208
Number of pages11
JournalOncology (Williston Park, N.Y.)
Volume31
Issue number3
StatePublished - Mar 15 2017
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Nanoparticle-Delivered Chemotherapy: Old Drugs in New Packages'. Together they form a unique fingerprint.

Cite this